What’s This About?
A new study published in the prestigious The Lancet Oncology
examined an innovative drug called Camizestrant in women with hormone-positive (ER+) and HER2-negative metastatic breast cancer,
whose disease progressed despite prior hormonal therapy
How Does It Work?
Camizestrant is a next-generation drug from the SERD group (Selective Estrogen Receptor Degraders), taken orally unlike the existing drug Fulvestrant which is given by injection
What Did They Find?
The results are particularly impressive!
- Time to disease progression was almost double with Camizestrant (7-8 months) compared to Fulvestrant (3.7 months)
- The drug proved to be safe with only mild side effects
- The 75mg dose was selected for further drug development
Why Is This Important?
This is significant news for many patients with metastatic breast cancer!
The new drug is not only more effective but also taken orally – which significantly eases treatment compared to injections
Remember, we are here for you Locating and supporting access to innovative drugs and advanced treatments for metastatic and stage 4 cancer patients worldwide
Share this post – it might help someone you know!
Yours, Nir Erez / Trial-In Pharma
Read the full article >>
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00387-5/abstract
